Display options
Cite
Lancellotti P, Galderisi M, Donal E, et al. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Fail. 2017;4(3):312-318doi: 10.1002/ehf2.12162.
Lancellotti, P., Galderisi, M., Donal, E., Edvardsen, T., Popescu, B. A., Farmakis, D., Filippatos, G., Habib, G., Lestuzzi, C., Santoro, C., Moonen, M., Jerusalem, G., Andarala, M., Anker, S. D. (2017). Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC heart failure, 4(3), 312-318. https://doi.org/10.1002/ehf2.12162
Lancellotti, Patrizio, et al. "Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology." ESC heart failure vol. 4,3 (2017): 312-318. doi: https://doi.org/10.1002/ehf2.12162
Lancellotti P, Galderisi M, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Lestuzzi C, Santoro C, Moonen M, Jerusalem G, Andarala M, Anker SD. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Fail. 2017 Aug;4(3):312-318. doi: 10.1002/ehf2.12162. Epub 2017 May 02. PMID: 28772051; PMCID: PMC5542718.
Copy Download .nbib Format: NLM
Share it on

ESC Heart Fail. 2017 Aug;4(3):312-318. doi: 10.1002/ehf2.12162. Epub 2017 May 02.

Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology.

ESC heart failure

Patrizio Lancellotti, Maurizio Galderisi, Erwan Donal, Thor Edvardsen, Bogdan A Popescu, Dimitrios Farmakis, Gerasimos Filippatos, Gilbert Habib, Chiara Lestuzzi, Ciro Santoro, Marie Moonen, Guy Jerusalem, Maryna Andarala, Stefan D Anker,

Affiliations

  1. University of Liège Hospital, GIGA Cardiovascular Science, Heart Valve Clinic, Imaging Cardiology, Liège, Belgium.
  2. Gruppo Villa Maria Care and Research, Anthea Hospital, Bari, Italy.
  3. Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy.
  4. Cardiologie, LTSI-INSERM U 1099, CHU Rennes, Université Rennes 1, Rennes, France.
  5. Department of Cardiology, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway.
  6. Centre of Cardiological Innovation, Oslo, Norway.
  7. Institute of Cardiovascular Diseases 'Prof. Dr. C. C. Iliescu', University of Medicine and Pharmacy 'Carol Davila'-Euroecolab, Bucharest, Romania.
  8. Cardio-Oncology Clinic, Heart Failure Unit, Department of Cardiology, University Hospital 'Attikon', National and Kapodistrian University of Athens, Athens, Greece.
  9. URMITE, Aix Marseille Université, UM63, CNRS 7278, IRD 198, INSERM 1095, IHU - Méditerranée Infection.
  10. APHM, La Timone Hospital, Cardiology Department, Marseille, France.
  11. Centro di Riferimento Oncologico (CRO), National Cancer Institute, Aviano, Italy.
  12. Department of Medical Oncology, CHU Sart Tilman Liège, University of Liège, Liège, Belgium.
  13. ESC EORP Department, Sophia Antipolis, France.
  14. Department of Cardiology and Pneumology, University Medicine Göttingen (UMG), Göttingen, Germany & DZHK (German Center for Cardiovascular Research).
  15. Division of Cardiology and Metabolism - Heart Failure, Cachexia & Sarcopenia; Department of Internal Medicine & Cardiology; and Berlin-Brandenburg Center for Regenerative Therapies (BCRT), at Charité University Medicine, Berlin, Germany.

PMID: 28772051 PMCID: PMC5542718 DOI: 10.1002/ehf2.12162

Abstract

AIMS: European Association of Cardiovascular Imaging/Heart Failure Association Cardiac Oncology Toxicity Registry was launched in October 2014 as a European Society of Cardiology multicentre registry of breast cancer patients referred to imaging laboratories for routine surveillance, suspected, or confirmed anticancer drug-related cardiotoxicity (ADRC). After a pilot phase (1 year recruitment and 1 year follow-up), some changes have been made to the protocol (version 1.0) and electronic case report form.

METHODS AND RESULTS: Main changes of the version 2.0 concerned exclusion criteria, registry duration, and clarification of the population characteristics. Breast cancer radiotherapy has been removed as an exclusion criterion, which involves now only history of a pre-chemotherapy left ventricular dysfunction. The period for long-term registry recruitment has been reduced (December 2017), but the target study population was extended to 3000 patients. The characteristics of the population are now better defined: patients seen in an imaging lab, which will include patients undergoing chemotherapy with associated targeted therapy or no targeted therapy, at increased risk of ADRC. In total, 1294 breast cancer patients have been enrolled, and 783 case report forms locked from October 2014 to November 2016. Of these, 481 (61.4%) were seen at first evaluation and 302 (38.6%) while on oncologic treatment with anticancer drugs. Fifty-two patients (17.2%) were not in targeted therapies, 191 (63.3%) were ongoing targeted therapy, and 59 (19.5%) had completed it. Twenty-three (2.9%) patients had a suspected diagnosis and 35 (4.5%) a confirmed diagnosis of ADRC. Arterial hypertension was the most prevalent cardiovascular risk factor (29.2%) followed by diabetes (6.1%). Previous history of heart failure accounted for 0.5%, whereas previous cardiac disease was identified in 6.3% of population.

CONCLUSION: The changes of the original protocol of the COT Registry and first update allow a first glance to the panorama of cardiovascular characteristics of breast cancer patients enrolled.

© 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

Keywords: Anticancer drug-related cardiotoxicity; Arterial hypertension; Cardiac imaging; Heart failure; Targeted therapy

References

  1. J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):141-6 - PubMed
  2. PLoS One. 2015 Jun 01;10(6):e0128891 - PubMed
  3. Eur Heart J. 2016 Sep 21;37(36):2768-2801 - PubMed
  4. ESC Heart Fail. 2015 Jun;2(2):85-89 - PubMed
  5. N Engl J Med. 2013 Jun 27;368(26):2527 - PubMed
  6. J Natl Cancer Inst. 2013 Jun 19;105(12):835-6 - PubMed
  7. Eur J Cancer. 2013 Apr;49(6):1374-403 - PubMed
  8. Eur Heart J Cardiovasc Imaging. 2014 Oct;15(10):1063-93 - PubMed
  9. Lancet Oncol. 2007 Sep;8(9):784-96 - PubMed
  10. J Clin Oncol. 1998 Nov;16(11):3493-501 - PubMed
  11. Curr Opin Oncol. 2014 Nov;26(6):590-9 - PubMed
  12. ESC Heart Fail. 2015 Sep;2(3):142-149 - PubMed
  13. Eur Heart J. 2016 Jul 14;37(27):2129-2200 - PubMed
  14. Eur Heart J Cardiovasc Imaging. 2015 May;16(5):466-70 - PubMed
  15. J Natl Cancer Inst. 2007 Mar 7;99(5):365-75 - PubMed
  16. N Engl J Med. 2011 Oct 6;365(14):1273-83 - PubMed
  17. Eur J Heart Fail. 2015 Jan;17(1):81-9 - PubMed
  18. ESC Heart Fail. 2017 Aug;4(3):312-318 - PubMed

Publication Types